Yarrow Bioscience director granted 15,435 stock options

Yarrow Bioscience, Inc. director Ashiya Mona reported a grant of stock options covering 15,435 shares of common stock on July 27, 2026.

Rhea-AI Filing Summary

Yarrow Bioscience, Inc. director Ashiya Mona reported a grant of stock options covering 15,435 shares of common stock on July 27, 2026. The options have a $28.5600 exercise price, expire on July 27, 2036, and vest in full on the earlier of July 27, 2027 or the next annual meeting of stockholders, subject to continued service. Under an agreement, Mona must transfer any securities issued, or their economic benefit, to OrbiMed Advisors LLC, which will provide them to OrbiMed Private Investments X, LP.

Insider Trade Summary

Grant/Award: 15,435 shares

Grant/Award 1 txn

Insider Ashiya Mona

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1, F2	15,435	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 15,435 contracts (Direct)

Footnotes (2)

1. F1. This option represents a right to purchase 15,435 shares of the Issuer's common stock, which vests in full on the earlier of (i) July 27, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the recipient's continued service to the Issuer.
2. F2. Pursuant to an agreement with OrbiMed Advisors LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments X, LP.

Key Figures

Stock options granted: 15,435 shares Exercise price: $28.5600 per share Expiration date: 2036-07-27 +1 more

4 metrics

Stock options granted 15,435 shares Stock option grant to director Ashiya Mona on 2026-07-27

Exercise price $28.5600 per share Exercise price for options covering 15,435 shares of common stock

Expiration date 2036-07-27 Expiration of stock options granted to Ashiya Mona

Derivative holdings after transaction 15,435 options Derivative securities beneficially owned following the reported grant

Key Terms

Stock Option (Right to Buy), vesting, annual meeting of the Issuer's stockholders, economic benefit, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

vesting financial

"which vests in full on the earlier of (i) July 27, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of the Issuer's stockholders financial

"the date of the next annual meeting of the Issuer's stockholders"

economic benefit financial

"or the economic benefit thereof, to OrbiMed Advisors LLC"

OrbiMed Private Investments X, LP financial

"provided to OrbiMed Private Investments X, LP."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ashiya Mona report at Yarrow Bioscience (YARW)?

Ashiya Mona reported a grant of stock options at Yarrow Bioscience covering 15,435 shares of common stock. The options were awarded on July 27, 2026 and are structured as a right to buy shares at a fixed exercise price.

How many Yarrow Bioscience shares are covered by Ashiya Mona's new options?

The new option grant covers 15,435 shares of Yarrow Bioscience common stock. These options give the holder the right to purchase that number of shares once vested, subject to the specified exercise price and other terms described in the grant.

What is the exercise price and expiration date of Ashiya Mona's YARW stock options?

The options have an exercise price of $28.5600 per share and expire on July 27, 2036. This means the holder can buy shares at $28.5600, if vested, any time up to that expiration date under the grant's conditions.

When do Ashiya Mona's Yarrow Bioscience stock options vest?

The options vest in full on the earlier of July 27, 2027 or the date of the next annual meeting of stockholders, in each case subject to continued service to Yarrow Bioscience. No partial vesting schedule is described in the disclosure.

Who ultimately receives the economic benefit from Ashiya Mona's YARW option grant?

Under an agreement with OrbiMed Advisors LLC, Ashiya Mona must transfer any securities issued from these options, or their economic benefit, to OrbiMed Advisors LLC, which will ensure they are provided to OrbiMed Private Investments X, LP.

How many derivative securities does Ashiya Mona hold after this Yarrow Bioscience transaction?

Following this transaction, the reported holdings show 15,435 stock options as derivative securities. This reflects the full amount of the new grant, as there were no exercises or disposals reported in connection with this Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/29/2026 - 09:37 PM Accepted by SEC EDGAR 07/29/2026 - 09:36 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ashiya Mona

(Last) (First) (Middle)

C/O YARROW BIOSCIENCE, INC.

470 JAMES STREET, SUITE 007

(Street)

NEW HAVEN CONNECTICUT 06513

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Yarrow Bioscience, Inc. [ YARW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$28.56	07/27/2026		A		15,435		(1)	07/27/2036	Common Stock	15,435	$0	15,435	D(2)

Explanation of Responses:

1. This option represents a right to purchase 15,435 shares of the Issuer's common stock, which vests in full on the earlier of (i) July 27, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the recipient's continued service to the Issuer.

2. Pursuant to an agreement with OrbiMed Advisors LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments X, LP.

	/s/ Tyler Zeronda, as attorney-in-fact for Mona Ashiya	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)